Primary Sjogren's Syndrome
9
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study
Exercise in Sjogren, Myositis and Takayasu's Arteritis
Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome
Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome